{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T09:22:52Z","timestamp":1697448172265},"reference-count":52,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,8,3]],"date-time":"2004-08-03T00:00:00Z","timestamp":1091491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>One of the best characterized resistance mechanisms of leukemias is multidrug resistance (MDR) mediated by P\u2010glycoprotein (Pgp) and multidrug\u2010resistant related protein (MRP). In addition to Pgp and MRP, p53 mutation or inactivation might play a relevant role in therapeutic failure. Some studies have demonstrated that Pgp and MRP may be activated in association with overexpression of mutant or inactivated p53 protein. The aim of this study was to investigate the association between p53 expression and MDR functional phenotype analyzed by flow cytometry (FCM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Rhodamine\u2010123 assay analyzed by FCM was used to detect the MDR phenotype that was positive in 18 out of 41 (43.9%) cases of chronic myeloid leukemia (CML), 16 out of 28 (57.1%) chronic lymphoid leukemia (CLL) cases, 11 out of 28 (39.3%) acute myeloid leukemia (AML) cases, and four out of 22 (18.2%) acute lymphoid leukemia (ALL) cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Variable levels of p53 expression were observed in leukemic cells: 12 out of 41 (29.2%) in CML, nine out of 28 (32.1%) in CLL, 15 out of 28 (53.6%) in AML, and eight out of 22 (36.4%) in ALL samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In our study, no significant association between p53 expression and MDR functional phenotype was observed in ALL, CLL, and AML. On the other hand, a significant association (<jats:italic>P<\/jats:italic> = 0.0003) of the coexpression was observed in CML. The p53 overexpression was more frequently seen in the accelerated phase and the blastic phase of this disease. Our results suggest that an MDR functional phenotype could be associated with p53 mutation in the advanced stage of leukemias. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.20013","type":"journal-article","created":{"date-parts":[[2004,8,3]],"date-time":"2004-08-03T21:32:35Z","timestamp":1091568755000},"page":"1-8","source":"Crossref","is-referenced-by-count":19,"title":["Coexpression of p53 protein and MDR functional phenotype in leukemias: The predominant association in chronic myeloid leukemia"],"prefix":"10.1002","volume":"61B","author":[{"suffix":"Jr.","given":"Geraldo Barroso","family":"Cavalcanti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia da Cunha","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giselle Pinto","family":"de Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Ant\u00f4nio Maur\u00edcio","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane de Almeida","family":"Dobbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudete Esteves","family":"Klumb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel C.","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,8,3]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"95","article-title":"Cellular mechanism of multidrug resistance of tumor cells","volume":"65","author":"Stavrovskaya AA","year":"2002","journal-title":"Biochemistry"},{"key":"e_1_2_6_3_2","first-page":"24","article-title":"Non P\u2010glycoprotein drug export mechanisms of multi\u2010drug resistance","volume":"34","author":"List AF","year":"1997","journal-title":"Sem Hematol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401694"},{"key":"e_1_2_6_5_2","first-page":"102","article-title":"Characterization of M (r) 190,000 multidrug resistance protein (MRP) in drug\u2010selected transfected human tumor cell","volume":"55","author":"Almquist KC","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00046-9"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00822.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290006080"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290026277"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02247.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00113-8"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10226"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1346476"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.20.11037"},{"key":"e_1_2_6_15_2","first-page":"71","article-title":"Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants","volume":"6","author":"Nguyen KT","year":"1994","journal-title":"Oncol Res"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9290"},{"key":"e_1_2_6_17_2","first-page":"5762","article-title":"Transcriptional suppression of multidrug resistance\u2010associated protein (MRP) gene expression by wild\u2010type p53","volume":"58","author":"Wang Q","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI12415"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/35106009"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19980301)31:3<180::AID-CYTO5>3.0.CO;2-P"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02054534"},{"key":"e_1_2_6_22_2","first-page":"2914","article-title":"Clinical utility of the immunocytochemistry detection of p53 protein in cytological specimens","volume":"54","author":"Dowell SP","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00094.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood.V90.10.4078","article-title":"Correlation between mutation in p53, p53 expression, cytogenetic, histologic type and survival in patients with B\u2010cell non\u2010Hodgkin's lymphoma","volume":"90","author":"Koduru PRK","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood.V84.8.2391.2391","article-title":"Structure and function of p53 in normal cells and their aberrations in cancer cells: projections on the hematologic cell lineages","volume":"84","author":"Prokocimer M","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08911.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000226"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200013"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0001-37652001000100007"},{"key":"e_1_2_6_31_2","first-page":"2161","article-title":"p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas","volume":"7","author":"Duthu A","year":"1992","journal-title":"Oncogene"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.47.9.843"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00094-2"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90187-2"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0371"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)00298-X"},{"key":"e_1_2_6_37_2","first-page":"1888","article-title":"Relationship between p53 gene mutation and multidrug resistance (mdr1) gene expression in myelodisplastic syndromes","volume":"7","author":"Preudhomme C","year":"1997","journal-title":"Leukemia"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.1998.00090.x"},{"key":"e_1_2_6_39_2","first-page":"2973","article-title":"Multidrug resistance related genes and p53 expression in human non small cell lung cancer","volume":"18","author":"Galimberti S","year":"1998","journal-title":"Anticancer Res"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9290"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2403057.x"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(90)90505-L"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.12.5455"},{"key":"e_1_2_6_44_2","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1182\/blood.V91.11.4342","article-title":"p53 expression in B\u2010chronic lymphocytic leukemia: a marker of disease progression and poor prognosis","volume":"91","author":"Cordone I","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1505.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood.V77.7.1500.1500","article-title":"Mutation of the p53 gene in human acute myelogenous leukemia","volume":"77","author":"Slingerland JM","year":"1991","journal-title":"Blood"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0371"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01378.x"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2002.03350.x"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.316"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002640000196"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120018235"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.6.2368"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.20013","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.20013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T21:26:46Z","timestamp":1696973206000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.20013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,3]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1002\/cyto.b.20013"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.20013","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,3]]}}}